4th Quarter - Report

340B HEALTH for 340B HEALTH

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$243,029
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 17, 2020 $243,029 Replaced
4th Quarter - Amendment Apr 21, 2020 $243,029 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

The 340B Drug Pricing Program; FY 2020 L-HHS Appropriations, S. 1895, Lower Health Care Costs Act, H.R. 3, Lower Drug Costs Now Act of 2019, S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019.

LobbyistCovered position, as disclosed
ELISE CRANSTON —
KATHRYN DIBITETTO —
GREG DOGGETT —
KATE ILAHI New Legislative Assistant, Congressman Charlie Melancon (D-LA)
AMANDA SELLERS SMITH —
MAUREEN TESTONI —

Contacted: HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); SENATE

Bills named: S. 2543 (116th), S. 1895 (116th), H.R. 3 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.